The novel available interferon (IFN)-free regimens significantly improved the sustained virological response (SVR) in patients with chronic hepatitis C (CHC), without important side effects and with shorter duration of treatment. In a subset of patients, however, the treatment failure (TF) was due to the presence of resistance-associated substitutions (RAS) that lead to virological breakthrough (BT) or relapse. We analysed in this case series the role of RAS on the TF in cirrhotic patients with genotype (GT)4, treated with a previous IFN-free regimen, and retreated with the combination of sofosbuvir (SOF)/velpatasvir (VEL) for 12 or 24 weeks, without ribavirin (RBV).

中文翻译：

---

用索非布韦/维帕他韦对既往无干扰素方案失败的基因型 4 肝硬化患者进行再治疗：病例系列。

新型可用的无干扰素 (IFN) 方案显着改善了慢性丙型肝炎 (CHC) 患者的持续病毒学应答 (SVR)，没有重要的副作用并且治疗持续时间更短。然而，在一部分患者中，治疗失败 (TF) 是由于存在导致病毒学突破 (BT) 或复发的耐药相关替代物 (RAS)。我们在这个案例系列中分析了 RAS 对基因型 (GT)4 肝硬化患者 TF 的作用，这些患者接受过先前的无 IFN 方案治疗，并用索非布韦 (SOF)/维帕他韦 (VEL) 联合治疗 12 或24 周，未使用利巴韦林 (RBV)。